Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 68-Ga RM2
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Andrei Iagaru
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 68-Ga RM2 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
May 14, 2019
Lead Product(s) : 68-Ga RM2
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Andrei Iagaru
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 68-Ga BAY86-7548
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Andrei Iagaru
Deal Size : Inapplicable
Deal Type : Inapplicable
68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer
Details : 68-Ga BAY86-7548 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
February 06, 2019
Lead Product(s) : 68-Ga BAY86-7548
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Andrei Iagaru
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 68-Ga RM2 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
January 18, 2019
Lead Product(s) : Autologous Platelet Rich Plasma
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Recipient : University of Wisconsin, Madison
Deal Size : Inapplicable
Deal Type : Inapplicable
Platelet-Rich Plasma Therapy for Patellar Tendinopathy
Details : Autologous Platelet Rich Plasma is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Tendinopathy.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 02, 2017
Lead Product(s) : Autologous Platelet Rich Plasma
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Recipient : University of Wisconsin, Madison
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Manganese-Enhanced Mri Contrast Reagent
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Recipient : Stanford University
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Trial of Manganese-Enhanced MRI (MEMRI) to Assess Peri-Infarct Injury
Details : Manganese-Enhanced Mri Contrast Reagent is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Ischemic Cardiomyopathy.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 14, 2016
Lead Product(s) : Manganese-Enhanced Mri Contrast Reagent
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Recipient : Stanford University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Acetylcysteine
Therapeutic Area : Nephrology
Study Phase : Phase IV
Recipient : VA Greater Los Angeles Healthcare System
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
Details : Acetylcysteine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Renal Insufficiency, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 19, 2015
Lead Product(s) : Acetylcysteine
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Recipient : VA Greater Los Angeles Healthcare System
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iodixanol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Recipient : Medical University of South Carolina
Deal Size : Inapplicable
Deal Type : Inapplicable
Aortic Stenosis Pre-Transcatheter Aortic Valve Replacement (TAVR) Procedure CT Scan
Details : Iodixanol is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Aortic Valve Stenosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 30, 2013
Lead Product(s) : Iodixanol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Recipient : Medical University of South Carolina
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
